@article{article_347453, title={Is there diagnostic and prognostic importance of serum anti-p53 antibody level in lung cancer?}, journal={Cumhuriyet Medical Journal}, volume={39}, pages={546–554}, year={2017}, DOI={10.7197/223.v39i31705.347453}, url={https://izlik.org/JA89PS69SB}, author={Hasbek, Zekiye and Yücel, Birsen and Doğan, Ömer Tamer and Berk, Serdar and Sarı, İsmail and Silig, Yavuz and Şeker, Mehmet Metin and Ertürk, Seyit Ahmet}, keywords={Anti-p53Antibody,lung cancer,F18-FDG,PET,p53}, abstract={<p class="Standard" style="margin-bottom:.0001pt;text-align:justify;line-height:normal;"> <b> <span lang="en-us" style="font-size:10pt;" xml:lang="en-us">Objective: </span> </b> <span lang="de" style="font-size:10pt;" xml:lang="de">Lung cancer is the leading cause
of cancer-related deaths worldwide. Despite advancement in diagnostic tools and
treatment options with technological developments, overall mortality rates in
lung cancer patients remains high. Survival rates in lung cancer patients is
low especially in advanced diseased inoperable patients in spite of new
treatment options like immunotherapy. p53 is mutated in 60-70% of cancer
patients and for this <span class="apple-converted-space">  </span> <span class="highlight" style="background-color:inherit;">reason </span> <span class="apple-converted-space">  </span>has been extensively <span class="highlight" style="background-color:inherit;">studied </span> recent researches suggest that serum
anti-p53Ab can be considered as biomarkers to detect many types of cancers; as
ovarian cancer, esophageal cancer, breast cancer and lung cancer. In this study
we aimed that are there any diagnostic and prognostic importance of serum
anti-p53Ab levels in lung cancer patients. </span> <span lang="de" style="font-size:10pt;" xml:lang="de"> </span> </p> <p> </p> <p class="Standard" style="margin-bottom:.0001pt;text-align:justify;line-height:normal;"> <b> <span lang="en-us" style="font-size:10pt;" xml:lang="en-us">Method: </span> </b> <span lang="de" style="font-size:10pt;" xml:lang="de">Patients were included who were
referred to our department with the purpose of <sup>18 </sup>F-FDG-PET/CT
imaging for staging due to lung cancer diagnosis (LC) and patients who were
performed <sup>18 </sup>F-FDG-PET/CT for diagnosis in the cause of the suspected
pulmonary nodule in thorax CT but not detected pathologic FDG accumulation
(NAPN=pulmonary nodule with non-avid-FDG) and healthy volunteers. Serum
anti-p53Ab levels were measured with ELISA method in the all patients. Mean
follow up time of patients were 13 months. </span> <span lang="de" style="font-size:10pt;" xml:lang="de"> </span> </p> <p> </p> <p class="Standard" style="margin-bottom:.0001pt;text-align:justify;line-height:normal;"> <b> <span lang="en-us" style="font-size:10pt;" xml:lang="en-us">Results: </span> </b> <span lang="de" style="font-size:10pt;" xml:lang="de">A total of 65 LC patients
(58M/7F), 47 patients with NAPN (20M/27F), and a total of 34 healthy volunteers
(26M/8F) were included in this study. Median serum anti-p53Ab levels are
3.4ng/mL in LC patients, 3.77ng/mL in NAPN patients, 3.07ng/mL in healthy
volunteers. There is no statistically significant difference for serum
anti-p53Ab level between LC patients and NAPN patients ( <i>p </i>=0.678). Moreover there is no statistically significant difference
for serum anti-p53Ab level between patients and healthy volunteers ( <i>p </i>=0.377). Two-year median survival of
patients was 14 month. It has been found that there is no effect of serum
anti-p53Ab level whether >3.4 or ≤3.4 on the patient survival rate ( <i>p </i>=0.652). </span> <span lang="de" style="font-size:10pt;" xml:lang="de"> </span> </p> <p> </p> <p class="Standard"> </p> <p class="Standard" style="margin-bottom:.0001pt;text-align:justify;line-height:normal;"> <b> <span lang="en-us" style="font-size:10pt;" xml:lang="en-us">Conclusions: </span> </b> <span lang="de" style="font-size:10pt;" xml:lang="de">Even though
anti-p53Ab is very important in carcinogenesis, we think that serum anti-p53Ab
level by itself is not important in lung cancer diagnosis and survival rates.
There are multiple factors in carcinogenesis and this may be the reason of this
situation. </span> <span lang="de" style="font-size:10pt;font-family:TimesNewRomanPSMT;" xml:lang="de"> </span> <span style="font-size:10pt;">There is no </span> <span style="font-size:10pt;">known cut off value of serum anti-p53 Ab levels for
diagnosis of lung cancer patients. </span> <span lang="de" style="font-size:10pt;" xml:lang="de"> Therefore we think that this antibody is not
tumor spesific and serum anti-p53 Ab level measurement is not appropriate for
lung cancer screening. </span> <span lang="de" style="font-size:10pt;" xml:lang="de"> </span> </p> <p> </p>}, number={3}